Introduction
During normal pregnancy, the female body undergoes physiologic changes in almost every organ system to harbor the growing fetoplacental unit. The hematologic system is no exception to this convention as the maternal blood undergoes changes both in quantity as well as its constitution. The constituents of maternal blood are testable to screen and diagnose a wide variety of conditions relating to both healthy pregnancies as well as diseases associated with pregnancy.
A little before reaching full term, the volume of maternal blood is about 30% above baseline. The excess is likely due to increased levels of estrogen and aldosterone, which cause the kidneys to retain higher amounts of fluid. A higher number of erythrocytes accompanies this excess fluid with a slightly increased mean corpuscular volume in a healthy pregnancy.[1] Therefore, at delivery, there are between 1 to 2 liters of excess blood in the maternal circulatory system.
The prominent hematologic changes are physiologic anemia, expanded plasma volume, mild thrombocytopenia, a mild prothrombotic state, and in some individuals, mild neutrophilia. Other than the above changes, maternal blood also contains a wide number of other antigens, proteins, and hormones of clinical significance.
Issues of Concern
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Issues of Concern
Certain findings fall outside the parameters of a normal physiologic pregnancy and require additional evaluation.
- Non-physiologic anemia: A hemoglobin level of less than 10 mg/dl is concerning and requires evaluation. Iron deficiency is common in pregnancy due to the increased iron demand. Iron deficiency is evidenced by new microcytosis or iron studies demonstrating low iron stores.
- Polycythaemia: Hemoglobin levels greater than 16 mg/dl should raise suspicion.
- Leukocytosis: An increase in neutrophils can occur in some cases, even in the absence of inflammatory conditions or infection. Further hematologic evaluation is necessary in case of a white blood cell (WBC) count greater than 20000/microL, marked lymphocytosis, or a differential showing immature myeloid forms.
- Leukopenia: An unexplained fall in the absolute neutrophil count below 1000/microL is concerning.
- Thrombocytopenia: Gestational thrombocytopenia is a common occurrence during pregnancy with platelet counts in the range of 80000 to 149000/microL.[2] Severe thrombocytopenia or thrombocytopenia with bleeding require further evaluation.
- Thrombocytosis: An increase in the platelet count of more than 500000/microL is unusual and requires investigation if unexplained.
Function
Maternal blood acts as the medium, which enables provision to the developing fetus of nutrients, gaseous exchange, and waste disposal. The placenta here serves as the gatekeeper of this exchange. Maternal blood floods the intervillous spaces, which is where the transfer takes place via both active and passive transport. Carbon dioxide, urea, uric acid, and creatinine are disposed into the maternal blood from the fetal circulation. Maternal blood contains IgG antibodies which diffuse through the placenta and provide naturally acquired passive immunity to the infant during the crucial first few months of life.
Related Testing
Initial Prenatal Screen
Prenatal care should be established in all women, ideally by ten weeks of pregnancy. Although the initial prenatal visit includes a history, physical examination, imaging studies, and blood work, in this section, we will only discuss the components of the prenatal evaluation that pertain to the maternal blood.
The tests commonly advocated in all patients are as follows:
- Hemoglobin, hematocrit, and mean corpuscular volume (MCV): To establish a baseline and screen for anemia.
- Rhesus type and ABO antibody screen: For the detection and prevention of alloimmunization and hemolytic disease of the newborn.
- Rubella and varicella immunity
- Syphilis, Hepatitis B, and HIV test
- Quadruple screen for fetal aneuploidies: This includes measuring maternal serum alpha-fetoprotein, beta-hCG, estriol, and inhibin A.
For special at-risk patients, the following tests may be undertaken:
- Serum TSH, T3, T4: For thyroid dysfunction only if symptomatic, personal or family history of dysfunction, or an associated condition.
- Diabetes mellitus type 2: The American Diabetes Association (ADA) and the American College of Obstetricians and Gynecologists (ACOG) recommend testing in early pregnancy for undiagnosed type 2 diabetes in women with risk factors.[3][4]
- Toxoplasmosis serology: For at-risk patients.
- Hemoglobin electrophoresis: Undertaken for patients with a high-risk ethnic background or an MCV of less than 80 fL unrelated to iron deficiency
- Lead levels: For patients at risk based on history.
Clinical Significance
Serum Human Chorionic Gonadotropin
Human chorionic gonadotropin (hCG) is a hormone produced by the syncytiotrophoblast cells of the placenta after implantation. The primary function of hCG is to maintain the corpus luteum and thus progesterone secretion for the first 8 to 10 weeks of pregnancy, after which the placenta takes over the function of hormone production, and the corpus luteum degenerates. The hCG serves as an important biomarker for the detection of pregnancy, disease states associated with pregnancy, diagnosis of aneuploidies as well as a tumor marker for gestational trophoblastic disease, and germ cell tumors. The detection of the beta subunit hCG serves as the basis of the pregnancy test.
Types of hCG Assay
- Immunometric sandwich-type assays are the routinely available commercial immunoassays for the quantification of serum hCG.
- Radioimmunoassays (RIAs): This is a competitive format assay based on the principle of competition between a fixed and known quantity of radiolabeled analyte and a sample analyte for a limited, fixed number of antibody binding sites.[5]
Conditions with Increased Levels of hCG
- Multiple gestations
- Hydatidiform moles
- Choriocarcinomas
- Down syndrome
Conditions with decreased levels of hCG
- Ectopic/failing pregnancy
- Edwards syndrome
- Patau syndrome
Anemia in Pregnancy
About 30 percent of women in the reproductive age group are anemic [6]. The World Health Organization (WHO) estimates that within the reproductive age group, the prevalence of anemia in pregnant women is even higher at around 40 percent. Given this high prevalence, recommendations for screening for anemia are at the first prenatal visit, with a repeat between 24 and 28 weeks of pregnancy.
As per the American College of Obstetricians and Gynecologists (ACOG) and the World Health Organization (WHO), anemia in pregnancy is defined as:[7][8][9]
- First trimester – Hemoglobin <11 g/dL
- Second trimester – Hemoglobin <10.5 g/dL
- Third trimester – Hemoglobin level <10.5 to 11 g/dL
Several causes lead to anemia in pregnancy, but chief among them are physiologic (dilutional) anemia of pregnancy and iron deficiency anemia.
- Physiologic anemia of pregnancy: This is the most common cause of anemia in pregnancy, though it is not a pathological condition. During normal pregnancy, there is a greater expansion of the plasma volume relative to the increase in the red cell mass, which results in dilutional anemia, termed as the physiologic anemia of pregnancy. Although this type of anemia is mild (hemoglobin of 10 to 11 g/dl), there is no specific hemoglobin or hematocrit value that can distinguish physiologic anemia from other causes of anemia in pregnancy.
- Iron deficiency anemia: It is the most common pathological cause of anemia during pregnancy. It may result from insufficient dietary intake, blood loss from menstruation or previous pregnancies, increased demand for iron during pregnancy, or impaired iron absorption from the gut.
Gestational Diabetes
Gestational diabetes has historically been defined as abnormal glucose tolerance with first onset or recognition during pregnancy.[10] Within the United States, the prevalence of gestational diabetes mellitus is roughly 6 percent.[11] Human placental lactogen secreted by the syncytiotrophoblasts of the placenta increases the overall insulin resistance. Since uncontrolled maternal blood glucose levels can result in several adverse outcomes for the mother and fetus, it is necessary to screen and treat gestational diabetes.
The most common method is 2-step testing:
- As a screening test, clinicians use the 50-gram one-hour glucose screen. The patient receives a 50-gram load of glucose irrespective of the last meal, followed in one hour by measuring the plasma glucose. As the threshold for a positive screen is increased from >130 mg/dl to > 140 mg/dl, there is a decrease in sensitivity and an increase in specificity.
- The diagnostic test mainly used is the 100 grams three-hour oral glucose tolerance test. After an 8 hour overnight fast, an oral glucose load of 100 grams is administered, and serum glucose levels measured at fasting, and then every hour for 3 hours post glucose administration. The threshold values are as follows:
- Fasting: 90 mg/dl
- 1 hour: 180 mg/dl
- 2 hour: 155 mg/dl
- 3 hour: 140 mg/dl
A glucose concentration greater or equal to these values at two or more points is considered a positive test.
RhD Alloimmunization in Pregnancy
When Rh-D negative women deliver an Rh-D positive baby or have any mixing of Rh-D positive blood, the maternal immune system develops an antibody response to the Rh-D antigen. During any subsequent pregnancy, an Rh-D positive fetus or neonate is at risk of suffering from the hemolytic disease of the newborn due to the maternal immune system attacking the fetal red blood cells owing to the prior activation against this antigen. Due to the morbidity and mortality associated with this preventable condition, Rhesus typing and an antibody screen should be performed at the initial prenatal visit and then again at 28 weeks. The standard methods of screening maternal blood include:
- Indirect Coombs
- Gel micro-column assay
- Automated enzymatic methods
The Kleihauer–Betke is a special test performed on maternal blood used to calculate the required dosage of Rh-D immune globulin to inhibit the formation of Rh antibodies in the mother and prevent Rh disease in the future Rh-positive children. It measures the quantity of fetal hemoglobin transferred into the maternal blood and, based on that, gives an estimate of the dose of Rh-D immune globulin required.
Cell-free DNA (cfDNA) Testing
CfDNA is produced by the mother as well as the fetoplacental unit. There are two sources of fetal cfDNA in maternal plasma. It can be either from the apoptosis of the syncytiotrophoblasts (placental cells) or the apoptosis of fetal erythroblasts, which generate cfDNA in fetal circulation, after which the fragments cross the placenta into the maternal circulation. These fragments of fetoplacental cfDNA can be extracted from maternal blood and analyzed for abnormalities. Fetal cfDNA first appears in maternal blood at five weeks of gestation and is always present at around nine weeks of gestation.[12]
Indications:
- Maternal age more > 35
- Abnormal maternal serum screening test
- Sonographic findings suggestive of fetal aneuploidy
- Fetal aneuploidy in a previous pregnancy
- Parental-balanced Robertsonian translocation
Applications:
1. Trisomies: cfDNA has the highest sensitivity for detecting aneuploidies such as trisomy 21, 18, and 13. The detection rate (DR) for the aneuploidies is as follows:[13][14][15][16]
- Trisomy 21: 99.5 %
- Trisomy 18: 97.7 %
- Trisomy 13: 96.1 %
2. Sex chromosome aneuploidies: Although based on the same principle, the cfDNA can help to detect sex chromosome aneuploidies, the DR is much lower than for the common autosomal aneuploidies.
3. Fetal sex determination
Maternal Serum Alpha-fetoprotein (MSAFP)
Alpha-fetoprotein is a globulin synthesized in the fetal yolk sac, liver as well as gastrointestinal tract. Although its function is unclear, it may play a role in immunoregulation and act as an intravascular transport protein. AFP is secreted into the fetal urine by the kidneys and then excreted into the amniotic fluid. From here, it finds its way into maternal serum, and this maternal serum alpha-fetoprotein can be measured to screen and diagnose certain conditions. MSAFP is measured at 15 to 20 weeks of gestation (optimally at 16 to 18 weeks) to screen for fetal anomalies.
Increase MSAFP levels:
- Open neural tube defects such as open spina bifida (meningomyelocele) or anencephaly
- Ventral wall defects like omphalocele and gastroschisis
- Multiple gestations
Decreased MSAFP levels:
- Aneuploidies (Trisomy 21 and trisomy 18)
Liver Disorders of Pregnancy
There are a few disorders of the hepatobiliary system that are unique to pregnancy and are diagnosable with blood work.
- Intrahepatic cholestasis of pregnancy: Presents with pruritis and jaundice in the late second or third trimester of pregnancy. Blood work shows elevated AST and ALT liver enzymes, bile acids, and bilirubin.
- HELLP syndrome: This condition presents with nausea, vomiting, epigastric and abdominal pain, and hypertension in the late second or third trimester of pregnancy. Laboratory studies show elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and bilirubin, platelets counts below 100,000 and schistocytes on the peripheral smear.
- Acute fatty liver of pregnancy: The patient has nausea, vomiting, anorexia, jaundice, and abdominal pain, usually in the third trimester of pregnancy. Some also have hypertension and proteinuria at presentation. Blood work demonstrates elevated AST, ALT, bilirubin, prothrombin time and international normalized ratio (PT/INR), and creatinine with decreased glucose and platelets.
References
Haram K, Nilsen ST, Ulvik RJ. Iron supplementation in pregnancy--evidence and controversies. Acta obstetricia et gynecologica Scandinavica. 2001 Aug:80(8):683-8 [PubMed PMID: 11531608]
Reese JA, Peck JD, Deschamps DR, McIntosh JJ, Knudtson EJ, Terrell DR, Vesely SK, George JN. Platelet Counts during Pregnancy. The New England journal of medicine. 2018 Jul 5:379(1):32-43. doi: 10.1056/NEJMoa1802897. Epub [PubMed PMID: 29972751]
. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstetrics and gynecology. 2018 Feb:131(2):e49-e64. doi: 10.1097/AOG.0000000000002501. Epub [PubMed PMID: 29370047]
American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes care. 2020 Jan:43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002. Epub [PubMed PMID: 31862745]
Stenman UH, Alfthan H. Determination of human chorionic gonadotropin. Best practice & research. Clinical endocrinology & metabolism. 2013 Dec:27(6):783-93. doi: 10.1016/j.beem.2013.10.005. Epub 2013 Oct 26 [PubMed PMID: 24275190]
Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. The Cochrane database of systematic reviews. 2011 Oct 5:(10):CD003094. doi: 10.1002/14651858.CD003094.pub3. Epub 2011 Oct 5 [PubMed PMID: 21975735]
Level 1 (high-level) evidenceAmerican College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: anemia in pregnancy. Obstetrics and gynecology. 2008 Jul:112(1):201-7. doi: 10.1097/AOG.0b013e3181809c0d. Epub [PubMed PMID: 18591330]
Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C, British Committee for Standards in Haematology. UK guidelines on the management of iron deficiency in pregnancy. British journal of haematology. 2012 Mar:156(5):588-600 [PubMed PMID: 22512001]
Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J, BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. British journal of haematology. 2020 Mar:188(6):819-830. doi: 10.1111/bjh.16221. Epub 2019 Oct 2 [PubMed PMID: 31578718]
. Proceedings of the 4th International Workshop-Conference on Gestational Diabetes Mellitus. Chicago, Illinois, USA. 14-16 March 1997. Diabetes care. 1998 Aug:21 Suppl 2():B1-167 [PubMed PMID: 9841138]
Deputy NP, Kim SY, Conrey EJ, Bullard KM. Prevalence and Changes in Preexisting Diabetes and Gestational Diabetes Among Women Who Had a Live Birth - United States, 2012-2016. MMWR. Morbidity and mortality weekly report. 2018 Nov 2:67(43):1201-1207. doi: 10.15585/mmwr.mm6743a2. Epub 2018 Nov 2 [PubMed PMID: 30383743]
Guibert J, Benachi A, Grebille AG, Ernault P, Zorn JR, Costa JM. Kinetics of SRY gene appearance in maternal serum: detection by real time PCR in early pregnancy after assisted reproductive technique. Human reproduction (Oxford, England). 2003 Aug:18(8):1733-6 [PubMed PMID: 12871892]
Taylor-Phillips S, Freeman K, Geppert J, Agbebiyi A, Uthman OA, Madan J, Clarke A, Quenby S, Clarke A. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ open. 2016 Jan 18:6(1):e010002. doi: 10.1136/bmjopen-2015-010002. Epub 2016 Jan 18 [PubMed PMID: 26781507]
Level 1 (high-level) evidenceMackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG : an international journal of obstetrics and gynaecology. 2017 Jan:124(1):32-46. doi: 10.1111/1471-0528.14050. Epub 2016 May 31 [PubMed PMID: 27245374]
Level 1 (high-level) evidenceIwarsson E, Jacobsson B, Dagerhamn J, Davidson T, Bernabé E, Heibert Arnlind M. Analysis of cell-free fetal DNA in maternal blood for detection of trisomy 21, 18 and 13 in a general pregnant population and in a high risk population - a systematic review and meta-analysis. Acta obstetricia et gynecologica Scandinavica. 2017 Jan:96(1):7-18. doi: 10.1111/aogs.13047. Epub 2016 Dec 9 [PubMed PMID: 27779757]
Level 1 (high-level) evidenceGil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015 Mar:45(3):249-66. doi: 10.1002/uog.14791. Epub 2015 Feb 1 [PubMed PMID: 25639627]
Level 1 (high-level) evidence